antibody

Monoclonal Anti- Epithelial cell adhesion molecule, EP-CAM

MBS355089

0.1 mg

275 USD

monoclonal

mouse

nonconjugated

[3-E1-E2]

human, mouse

western blot, immunohistochemistry, immunocytochemistry, flow cytometry, FACS

Antibody

Monoclonal Anti- Epithelial cell adhesion molecule, EP-CAM

[Epithelial cell adhesion molecule, EP-CAM]

[Monoclonal Anti- Epithelial cell adhesion molecule; EP-CAM]

[Epithelial cell adhesion molecule; Epithelial cell adhesion molecule; epithelial cell adhesion molecule; epithelial glycoprotein 314; human epithelial glycoprotein-2; cell surface glycoprotein Trop-1; adenocarcinoma-associated antigen; tumor-associated calcium signal transducer 1; major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein); epithelial cell adhesion molecule; Adenocarcinoma-associated antigen; Cell surface glycoprotein Trop-1; Epithelial cell surface antigen; Epithelial glycoprotein; EGP; Epithelial glycoprotein 314; EGP314; hEGP314; KS 1/4 antigen; KSA; Major gastrointestinal tumor-associated protein GA733-2; Tumor-associated calcium signal transducer 1]

[EP-CAM]

[EPCAM; EPCAM; ESA; KSA; M4S1; MK-1; DIAR5; EGP-2; EGP40; KS1/4; MIC18; TROP1; EGP314; HNPCC8; TACSTD1; GA733-2; M1S2; M4S1; MIC18; TACSTD1; TROP1; Ep-CAM; EGP; EGP314; hEGP314]

EPCAM_HUMAN

Monoclonal

IgM

[3-E1-E2]

Mouse

Human, mouse

Protein affinity purified

Liquid; In TBS (pH7.4), 0.5% BSA, 40% Glycerol and 0.05% Sodium Azide.

Store at 4°C after thawing (1 week). Aliquot and store at -20°C for long term (at least one year). Avoid repeated freeze and thaw cycles.

Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Flow Cytometry (FC/FACS)

Western Blot (1:1000-2000). Immunohistochemistry (1:200-500). Immunocytochemistry (1:100-200). Flow Cytometry (1:100-200). Other applications have not been tested. The optimal dilutions should be determined by end user.

Western Blot (WB)

Immunohistochemistry (IHC)

Immunogen: Recombinant EP-CAM protein.

Epithelial cell adhesion molecule (Ep-CAM) is a pan-epithelial differentiation antigen. [1]It is intricately linked with the Cadherin-Catenin pathway and hence the fundamental WNT pathway responsible for intracellular signalling and polarity. It has been used as an immunotherapeutic target in the treatment of gastrointestinal, urological and other carcinomas. [2]It is expressed in undifferentiated pluripotent stem cells. [3] and it is being used as a target for immunotherapy treatment of human carcinomas.

1. Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S (Apr 2001). "Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization". Cytogenet Cell Genet 92 (1-2): 164-5. 2. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC (April 2007). "EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges". Br. J. Cancer 96 (7): 1013-9. 3. Sundberg, M; Jansson, L; Ketolainen, J; Pihlajamäki, H; Suuronen, R; Skottman, H; Inzunza, J; Hovatta, O et al. (2009). "CD marker expression profiles of human embryonic stem cells and their neural derivatives, determined using flow-cytometric analysis, reveal a novel CD marker for exclusion of pluripotent stem cells.". Stem cell research 2 (2): 113-24.

15928632

AAH14785.1

P16422

This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy. [provided by RefSeq, Dec 2008]

Function: May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E. Ref.13 Ref.14 Ref.19 Ref.20. Subunit structure: Monomer. Interacts with phosphorylated CLDN7. Ref.11 Ref.15. Subcellular location: Lateral cell membrane; Single-pass type I membrane protein. Cell junction tight junction. Note: Co-localizes with CLDN7 at the lateral cell membrane and tight junction. Ref.13 Ref.15 Ref.20. Tissue specificity: Highly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma. Ref.19. Post-translational modification: Hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability. Ref.12 Ref.16. Involvement in disease: Diarrhea 5, with tufting enteropathy, congenital (DIAR5) [MIM:613217]: An intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.22Hereditary non-polyposis colorectal cancer 8 (HNPCC8) [MIM:613244]: An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.Note: The disease is caused by mutations affecting the gene represented in this entry. HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM. Ref.18. Sequence similarities: Belongs to the EPCAM family.Contains 1 thyroglobulin type-1 domain.

0.1 mg

275 USD